Table 2. Optimal combination of IC proteins in patients with HMs.

IC combination	Stage	Detection method	HM patients
IC, immune checkpoint; HM, hematological malignancy; PD-1, programmed cell death 1; CTLA-4, cytotoxic T-lymphocyte associated protein 4; PD-L2, PD ligand 2; TIM-3, T cell immunoglobulin domain and mucin domain-3; TIGIT, T cell immunoreceptor with Ig and ITIM domains; LAG-3, lymphocyte-activation gene 3; VISTA, V-domain Ig suppressor of T cell activation; qRT-PCR, quantitative real-time polymerase chain reaction; IHC, immunohistochemistry; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NK/TCL, natural killer/T-cell lymphoma.
PD-1/CTLA-4	De novo	qRT-PCR	AML
PD-L2/CTLA-4	De novo	qRT-PCR	AML
PD-1/TIM-3	De novo	Flow cytometry	AML
PD-1/TIGIT	De novo	Flow cytometry	AML
CTLA-4/LAG-3	De novo	Flow cytometry	AML
PD-1/TIGIT	De novo	qRT-PCR	MDS
PD-1/CD47	De novo	qRT-PCR	MDS
TIGIT/CD47	De novo	qRT-PCR	MDS
VISTA/PD-L1	De novo	IHC	Extranodal NK/TCL